Clinical spectrum of pulmonary inflammatory myofibroblastic tumor
Shin-ichi Takeda 1*,
Yasuyo Onishi 2,
Tomohiro Kawamura 1,
Hajime Maeda 1
1 Toneyama National Hospital, Toyonaka City, Osaka, Japan
2 Ootemae Hospital, Chuou-ku, Osaka, Japan
* To whom correspondence should be addressed. E-mail: stakeda{at}gh.pref.osaka.jp.
 |
Abstract |
|---|
We retrospectively describe clinicopathological characteristics of 5 patients with surgically resected pulmonary inflammatory myofibroblastic tumor (IMT), and discuss in the light of present-day concepts regarding this disease entity. During the past 15 years, 5 patients with an age ranging from 21 to 74 years underwent a surgery for IMT of the lung, and the resected lesions were studied histologically and immunohistochemically. Three asymptomatic patients referred as X-ray suspicious lung cancer, one patient complained of recurrent hemoptysis, and 1 presented with fever and dyspnea. The 3 patients were treated by lobectomy (n=3) including chest wall resection, 1 segmentectomy and 1 wedge resection, 2 of whom were diagnosed as pulmonary sarcoma by frozen section at surgery. The tumor size ranged from 1.5 to 5.5 cm in diameter and histologically characterized by myofibroblasts that are mixed with chronic inflammatory cells, including plasma cells, lymphocytes, and histiocytes. There was no recurrence in these patients, and all of them are in good health. Complete surgical resection can be chosen for both diagnostic and therapeutic for IMTs, which remains the best treatment. Keywords: Inflammatory myofibroblastic tumor (IMT); Inflammatory pseudotumor; Rare pulmonary neoplasm
